Premium
Albumin‐Coated Amberlite XAD‐7 Resin for Hemoperfusion in Acute Liver Failure: Part II: In Vivo Evaluation
Author(s) -
Hughes Robin,
Ton Hsueh Yen,
Langley Peter,
Davies Michael,
Hanid M. Anwar,
Mellon Peter,
Silk David B. A.,
Williams Roger
Publication year - 1979
Publication title -
artificial organs
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.684
H-Index - 76
eISSN - 1525-1594
pISSN - 0160-564X
DOI - 10.1111/j.1525-1594.1979.tb03800.x
Subject(s) - amberlite , hemoperfusion , albumin , bilirubin , chemistry , in vivo , serum albumin , chromatography , medicine , surgery , gastroenterology , organic chemistry , adsorption , hemodialysis , microbiology and biotechnology , biology
Albumin‐coated Amberlite XAD‐7 has been previously shown to be blood compatible in in vitro hemoperfusion experiments with human blood. In this study, the preliminary results are Reported on single hemoperfusions with albumin‐coated XAD‐7 resin in four patients with acute liver failure. The mean platelet count was 116 ± SE 16.3% of the initial arterial value and the mean white cell count was 96 ± SE 6.5% of initial at the end of four hours of hemoperfusion. Removal of bilirubin, phenols and substances in the middle molecular weight range by the resin was demonstrated. These preliminary results suggest albumin‐coated Amberlite XAD‐7 resin to be blood compatible and capable of removing protein‐bound and middle molecular weight substances from patients with acute liver failure. Further clinical evaluation of repeated resin hemoperfusion is required to determine whether this treatment will be beneficial to patient survival.